Evaluating the survival impact of chemotherapy after surgery for Stage I pancreatic cancer
The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer Stratified by Pathologic Risk Factors
This study is trying to see if chemotherapy after surgery can help people with Stage I pancreatic cancer live longer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tianjin Medical University Cancer Institute and Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Tianjin, Tianjin) |
| Trial ID | NCT06208436 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the effects of adjuvant chemotherapy on the survival rates of patients diagnosed with Stage I pancreatic cancer who have undergone surgical resection. It aims to stratify patients based on pathologic risk factors to better understand the potential benefits of chemotherapy in this specific population. By analyzing data from patients treated between 2010 and 2021, the study seeks to provide insights into the effectiveness of chemotherapy in improving outcomes for these patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who have undergone surgical resection for pathologically confirmed Stage I pancreatic ductal adenocarcinoma (PDAC).
Not a fit: Patients who have more advanced disease stages, received neoadjuvant therapy, or experienced perioperative mortality are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide evidence supporting the use of adjuvant chemotherapy to enhance survival rates in patients with Stage I pancreatic cancer.
How similar studies have performed: Other studies have shown varying success with adjuvant chemotherapy in pancreatic cancer, but this specific focus on Stage I patients is less commonly explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients who underwent surgical resection and were pathologically diagnosed as PDAC between 2010 and 2021. - Exclusion Criteria: Patients with pN1-N2, patients with pT3-T4, patients with distant metastasis, patients who received neoadjuvant therapy, patients with R1 resection, and patients who died due to perioperative mortality within 30 days. -
Where this trial is running
Tianjin, Tianjin
- Jihui — Tianjin, Tianjin, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.